Lead-212 PSV359 Therapy for Patients With Solid Tumors

Phase I/IIa image-guided, alpha-particle therapy study of \[203Pb\]Pb-PSV359 and \[212Pb\]Pb-PSV359 in patients with solid tumors that are known to be Fibroblast Activation Protein (FAP)-positive.

Trial Details

NCT ID
NCT06710756
Phase
PHASE1 / PHASE2
Sponsor
Perspective Therapeutics
Status
RECRUITING
Cancer Type
Sarcoma
Interventions
  • [203Pb]Pb-PSV359
  • [212Pb]Pb-PSV359
Locations (sample)
  • Los Angeles, California, United States|34.05223,-118.24368
  • Los Angeles, California, United States|34.05223,-118.24368
  • Miami, Florida, United States|25.77427,-80.19366
  • Miami, Florida, United States|25.77427,-80.19366
  • Kansas City, Kansas, United States|39.11417,-94.62746

Key Eligibility Criteria

  • Aged ≥ 18 years
  • Satisfactory organ function as determined by laboratory testing
  • Eastern Cooperative Oncology Group performance (ECOG) status of 0 to 1
  • Life expectancy \> 3 months

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Sarcoma Trials on Trialify →